Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization

Recruiting now · Not applicable

Conditions studied: Corneal Neovascularisation

In brief

The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization. The main questions it aims to answer are: Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients? Participants will: Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms. Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.

Key facts

Study ID

NCT07642960

Run by

HoChiMinh City Eye Hospital

People needed

51

Starts

2026-04-01

Expected to finish

2028-04-01

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age over 18 years.
• Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination.
• Corneal neovascularization is stable with no evidence of progression for at least 4 weeks.
• Agreement to participate in the study and ability to comply with outpatient follow-up requirements

You may not qualify if…

• Pregnant or breastfeeding women.
• History of hypersensitivity or allergy to bevacizumab or any component of the study medication.
• Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease.
• Active ocular infection or acute conjunctivitis at the time of enrollment.
• Persistent corneal epithelial defect or delayed corneal epithelial healing.
• History of ocular surgery within 3 months before study enrollment.
• Corneal neovascularization associated with uncontrolled secondary glaucoma.
• Inability or unwillingness to comply with study treatment or follow-up visits.

Where it is running

• HoChiMinh City Eye Hospital — Ho Chi Minh City, Xuan Hoa, Vietnam (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.